Please assess the completion status of the following clinical trial:

Trial Title: Oral Valganciclovir Versus Valacyclovir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving alemtuzumab~* Age \> 15~* Signed informed consent form~Exclusion Criteria:~* Active cytomegalovirus disease or infection. Asymptomatic patients with positive CMV pp65 antigenemia will not be excluded.~* Patients with a creatinine clearance of \< 10 ml/min as calculated via the Cockcroft-Gault equation.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Valacyclovir
- 2 (Type: ACTIVE_COMPARATOR): Valganciclovir

Based on this trial design, predict the completion outcome and termination type (if applicable).